Fortress Biotech Inc (FBIO)vsNovartis AG ADR (NVS)
FBIO
Fortress Biotech Inc
$1.99
-1.00%
HEALTHCARE · Cap: $64.37M
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 83685% more annual revenue ($57.36B vs $68.47M). FBIO leads profitability with a 163.3% profit margin vs 17.5%. FBIO trades at a lower P/E of 0.7x. FBIO earns a higher WallStSmart Score of 60/100 (C).
FBIO
Buy60
out of 100
Grade: C
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+73.0%
Fair Value
$13.57
Current Price
$1.99
$11.58 discount
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 163 of every $100 in revenue as profit
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -108.7% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : FBIO
The strongest argument for FBIO centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 163.3% and operating margin at -53.5%. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : FBIO
The primary concerns for FBIO are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
FBIO profiles as a mature stock while NVS is a value play — different risk/reward profiles.
FBIO carries more volatility with a beta of 1.26 — expect wider price swings.
FBIO is growing revenue faster at 14.0% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
FBIO scores higher overall (60/100 vs 48/100), backed by strong 163.3% margins and 14.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortress Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?